Abstract
Background Random forest model is a recently developed machine-learning algorithm, and superior to other machine learning and regression models for its classification function and better accuracy. But it is rarely used for predicting causes of death in lung cancer patients. On the other hand, specific causes of death in lung cancer patients are poorly classified or predicted, largely due to its categorical nature (versus binary death/survival).
Methods We therefore tuned and employed a random forest algorithm (Stata, version 15) to classify and predict specific causes of death in lung cancer patients, using the surveillance, epidemiology and end results-18 and several clinicopathological factors. The lung cancer diagnosed during 2004 were included for the completeness in their follow-up and death causes. The patients were randomly divided into training and validation sets (1:1 match). We also compared the accuracies of the final random forest and multinomial regression models.
Results We identified and randomly selected 40,000 lung cancers for the analyses, including 20,000 cases for either set. The causes of death were, in descending ranking order, were lung cancer (72.45 %), other causes or alive (14.38%), non-lung cancer (6.87%), cardiovascular disease (5.35%), and infection (0.95%). We found more 250 iterations and the 10 variables produced the best prediction, whose best accuracy was 69.8% (error-rate 30.2%). The final random forest model with 300 iterations and 10 variables reached an accuracy higher than that of multinomial regression model (69.8% vs 64.6%). The top-10 most important factors in the random-forest model were sex, chemotherapy status, age (65+ vs <65 years), radiotherapy status, nodal status, T category, histology type and laterality, which were also independently associated with 5-category causes of death.
Conclusion We optimized a random forest model of machine learning to predict the specific cause of death in lung cancer patients using a set of clinicopathologic factors. The model also appears more accurate than multinomial regression model.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The informed consent was not obtained for the SEER patients due to de-identified nature of the dataset. Owing to the use of publicly available, de-identified SEER cases, this study was exempt from an institutional review board approval. However, we have received the approval for using the SEER-18 data under the condition of compliance with their preset terms (user ID lzhang). Moreover, all 50 states in the USA have laws requiring newly diagnosed cancers to be reported to a central registry. The state cancer registries in the SEER program would deposit their extracted, de-identified cancer data to the SEER database after meeting quality control standards (www.seer.cancer.gov). Thus, the SEER data collection was authorized by the US state laws, and supervised by respective state public-health officials and ethical review committees.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The SEER data were available upon request to the SEER website (www.seer.cancer.gov). All other data are available upon request.
